Community-acquired PneumoniaNCT03098914
Clinical Characteristics and Microbiology of Community-Acquired Pneumonia
An observational study of Community-acquired Pneumonia, run by Beijing Haidian Hospital at 1 site in China.
Trial summary
Community-Acquired Pneumonia has become common. Additionally, the mortality is high. But the epidemiology of pathogen is various in different areas, which is crucial for the key treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Community-acquired Pneumonia
- What is being tested?
- Cohort Study； pathogen； clinical features
- How many people
- 2,000 participants
- Where
- 1 siteChina
- Study dates
- 11 Apr 2017to 1 May 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients with commnuity acquired pneumonia
Who may be able to join
- Confirmed community acquired pneumonia
- Age≥18 ys
Who cannot join
- HIV infection
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Beijing Haidian Hospital
Beijing, Beijing Municipality, 100000
Liu Chao, Master, +86 18614043137, liuchao3619@163.com
About this study
Official title: Clinical Characteristics and Microbiology of Community-Acquired Pneumonia: A Prospective Study
Community-Acquired Pneumonia has become common. Additionally, the mortality is high. But the epidemiology of pathogen is various in different areas, which is crucial for the key treatment. In addition, the risk factors of patients who died in 3 or 7 days in china is not clear, comparing with patients who died in 14 or 28 days or who survived.
- Conditions
- Community-acquired Pneumonia
- Being tested
- Cohort Study； pathogen； clinical features
- Keywords
- Pathogen, Mortality, Community-acquired Pneumonia, Risk factors
- Medical subject headings
- Community-Acquired Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cohort Study； pathogen； clinical featuresOther
Cohort Study； pathogen； clinical features
| Study group | Role | What they receive |
|---|---|---|
| Beijing Haidian Hospital | Not described Receives: Other: Cohort Study； pathogen； clinical features | |
| Chinese PLA General Hospital | Not described Receives: Other: Cohort Study； pathogen； clinical features | |
| Beijing Tsinghua Chang gung Hospital | Not described Receives: Other: Cohort Study； pathogen； clinical features |
What is being measured
The primary outcome is the main question the study is designed to answer.
the epidemiology of pathogen of community-acquired pneumonia in the three hospitals
screen out the pathogen of community-acquired pneumonia
Measured: confirmed as community-acquired pneumonia （2 weeks）
Secondary outcomes (1)
risk factors of patients who died in 3 or 7 days
patients who die in 3 or 7 days
Measured: in one week（3 days or 7days）
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2017
- Study start11 Apr 2017 (estimated)
- Primary completion1 Apr 2019 (estimated)
- Study completion1 May 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Community-acquired PneumoniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Haidian Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Liu chao, Beijing Haidian Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03098914
- Sponsor's protocol ID
- Beijing Haidian Hospital
- Status last verified
- Apr 2017
- First submitted
- 22 Mar 2017
- Last updated
- 5 Apr 2017
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Apr 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Characteristics and Microbiology of Community-Acquired Pneumonia: A Prospective Study
- ClinicalTrials.gov ID
- NCT03098914
- Acronym / sponsor ID
- Beijing Haidian Hospital
- Conditions
- Community-acquired Pneumonia
- Keywords
- Pathogen, Mortality, Community-acquired Pneumonia, Risk factors
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Beijing Haidian HospitalUniversity, hospital or other
- Collaborators
- Beijing Tsinghua Chang Gung Hospital, Chinese PLA General Hospital
- Study start
- 11 Apr 2017 (estimated)
- Primary completion
- 1 Apr 2019 (estimated)
- Study completion
- 1 May 2019 (estimated)
- First posted
- 4 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Community-Acquired Pneumonia has become common. Additionally, the mortality is high. But the epidemiology of pathogen is various in different areas, which is crucial for the key treatment. In addition, the risk factors of patients who died in 3 or 7 days in china is not clear, comparing with patients who died in 14 or 28 days or who survived.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Beijing Haidian Hospital | – | Other: Cohort Study； pathogen； clinical features |
| Chinese PLA General Hospital | – | Other: Cohort Study； pathogen； clinical features |
| Beijing Tsinghua Chang gung Hospital | – | Other: Cohort Study； pathogen； clinical features |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients with commnuity acquired pneumonia
Key inclusion criteria (2 listed)
- Confirmed community acquired pneumonia
- Age≥18 ys
Key exclusion criteria (1 listed)
- HIV infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cohort Study； pathogen； clinical featuresCohort Study； pathogen； clinical features | Other | Beijing Haidian Hospital, Beijing Tsinghua Chang gung Hospital, Chinese PLA General Hospital |
Primary outcome
the epidemiology of pathogen of community-acquired pneumonia in the three hospitals
Time frame: confirmed as community-acquired pneumonia （2 weeks）
screen out the pathogen of community-acquired pneumonia
1 secondary outcome
risk factors of patients who died in 3 or 7 days
Time frame: in one week（3 days or 7days）
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Apr 2017.
Related trials for Community-acquired Pneumonia
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
Not yet recruitingPhase 4
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
Community Acquired Pneumonia (CAP)
Active, not recruitingPhase 2/3
Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia
Community-acquired Pneumonia, CAP
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Community-acquired Pneumonia, run by Beijing Haidian Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the epidemiology of pathogen of community-acquired pneumonia in the three hospitals (time frame: confirmed as community-acquired pneumonia （2 weeks）). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Apr 2017.